Preleukemia  >>  Soliris (eculizumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT00122330: Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Completed
3
75
US, Canada, Europe, RoW
eculizumab
Alexion Pharmaceuticals
Hemoglobinuria, Paroxysmal
 
01/06
NCT00122304 / 2004-002795-42: Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Completed
3
85
US, Canada, Europe, RoW
eculizumab
Alexion Pharmaceuticals
Hemoglobinuria, Paroxysmal
 
11/06
NCT00122317 / 2005-000043-28: Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Completed
3
187
US, Canada, Europe, RoW
eculizumab, Soliris
Alexion Pharmaceuticals
Paroxysmal Hemoglobinuria, Nocturnal
09/08
10/08

Download Options